Common Sense Ltd.

www.cs-commonsense.com

Now Peptonic Israel

High-Tech Company

Acquired by Peptonic

Graduated from: Abital

TECH VERTICALS

Diagnostics, FemTech, Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	1999
Number of Employees	16
Reg. Number:	abCDe

DESCRIPTION

Common Sense is a leading developer and manufacturer of indicators utilizing common hygienic products such as panty-liners, tampons and diapers as a platform for non-intrusive diagnosis and health condition monitoring. Common Sense also develops and manufactures unique, easy to use, Point of Care diagnostic solutions which assist physicians in determining the source of various vaginal infections.

TECHNOLOGY

Based on its innovative technologies, Common Sense develops a set of vaginal diagnostic products for short, mid and long-term launches. All products are based on clearly identified and analyzed market needs, confirmed by consumers, leading market players and potential business partners.

Sampling and testing of human body fluids are the most common among modern diagnostic technologies. Self-testing and self-sampling save time and give the users better daily control on their health.

The market for home-testing and self-sampling of vaginal discharge is ripe for new technologies and products. Vaginal secretions are traditionally collected by physicians, using a speculum and inserting swabs. This is extremely awkward and uncomfortable procedure.

The latest research proves that the same test results can be obtained via natural vaginal discharge. The results of this research paves the path for the development of a series of non-intrusive products for sampling and testing.

Products and Phases

Product	Phase
AL-SENSE(TM)	Approved CE Approved Health Canada, TGA
The AL-SENSE™ Amniotic fluid detection kit is an in vitro self-test that allows detection of possible amniotic fluid leakage in the event of pregnant women sensing unidentified vaginal wetness. AL-SENSE™ can distinguish between amniotic fluid leak (positive result) and urine (negative result). It is easy to use and results reading is clear Yes/No with no need for color scale. Home use and professional use.
VA-SENSE(TM)	FDA Approved CE Approved
The VS-SENSE™ TEST is a qualitative, visually-read swab for clinicians who wish to evaluate women with vaginal symptoms to rule out or rule in Bacterial Vaginosis and Trichomoniasis. The test indicates by color change whether a vaginal secretion has disordered acidity parameters. Results are based on combined indication of pH level and buffer capacity (watery secretion) which characterizes Bacterial Vaginosis and Trichomoniasis. The VS-SENSE™ Test indicates abnormal vaginal discharge acidity by identifying changes in the pH level. The test cutoff is set at pH 4.7 (+0.3/-0.2 pH units; there may be variations due to sensitivity to buffer capacity). When the vaginal secretion has a pH above this cutoff, the test tip will be stained (or partially stained) green or blue. The test, when combined with clinical examination, assists the physician in diagnosing conditions which are associated with elevated pH levels.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Women with vaginal symptoms / Pregnant women.

	BUSINESS MODEL
	B2C

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Patent Attorneys
abC Defghij	Accounting Firm
abC Defghij	Law Firm

CONTACT INFO

Expand / Collapse All

Main Address: Caesarea, Israel

Address	7 Haeshel St., Zone 2, Caesarea Industrial Park
POB	3567
City	Caesarea
Country	Israel
Zip	3088900

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: New York, United States

City	New York
State/Province	NY
Country	United States

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Dan Hod	Co-Founder

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Oct. 11, 2021

Initial Revenues

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Third Round

Mar. 01, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe

Second Round

Mar. 01, 2004

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Holdings sold.
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe	02/2007: Holdings sold.
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

First Round

Mar. 01, 2000

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Investment was made by Mediseed; the company is held by BMI
abC Defghij	Venture Capital Fund	abCDe	Holdings sold.
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

Seed

Mar. 01, 1999

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Mar. 01, 1999

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe